Novogen's TRXE-009 shows potential By: MarketMinute.com Stock News March 04, 2015 at 13:14 PM EST Novogen Ltd. (Nasdaq: NVGN) announced that TRXE-009 demonstrated potential to kill brain cancer stem cells sending the stock price soaring $1.09 to $3.61.